Drug intelligence / Profile preview

dextromethorphan + phenylephrine

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

Dextromethorphan + phenylephrine is an oral combination pharmaceutical product used primarily for the **temporary relief of cough and nasal congestion** associated with the common cold, flu, and upper respiratory tract infections. - **Dextromethorphan** is a non-opioid antitussive (cough suppressant) that acts centrally on the cough center in the medulla oblongata to reduce the cough reflex, without the analgesic or addictive properties associated with opioid cough suppressants. - **Phenylephrine** is a sympathomimetic decongestant that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction in nasal mucosa to decrease swelling and congestion. This combination does not treat the underlying infection or cause of symptoms, but provides symptomatic relief. It is available over-the-counter in various formulations, sometimes as part of multi-ingredient cough/cold preparations[5][8].

02

Targets

SERT (Sodium-dependent serotonin transporter)ADRA1A (α1A)SIGMAR1 (Sigma non-opioid intracellular receptor 1)DRD (Dopamine receptors)ADRA1B (α1B)ADRA1D (α1D)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on dextromethorphan + phenylephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dextromethorphan + phenylephrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call